TAG:
U.S. Securities and Exchange Commission
Change Healthcare Hit by Major Cyberattack
By Robert Michel | From the Volume XXXI, No. 4 – March 18, 2024 Issue
CEO SUMMARY: It was a classic ransomware attack against Change Healthcare, the business unit of Optum that is itself a division of UnitedHealth Group. On Feb. 21, this cyberattack shut down critical systems at Change Healthcare, such as those involved in accepting and forwarding prescript…
Genetics Company 23andMe Shares Update on Cyberattack
By Robert Michel | From the Volume XXXI, No. 4 – March 18, 2024 Issue
CONSUMER GENETICS HEALTHCARE AND BIOPHARMACEUTICAL COMPANY 23ANDME recently revealed that unauthorized access to millions of its customers’ personal information may have started earlier than the company previously reported. In its original U.S. Securities and Exchange Co…
Genetic Testing Firm Invitae Files Chapter 11 Bankruptcy, Pursues Sale
By Robert Michel | From the Volume XXXI, No. 3 – February 26, 2024 Issue
INVITAE CORP., A MEDICAL GENETICS COMPANY, got the go ahead in mid-February from the U.S. Bankruptcy Court for the District of New Jersey “to find a buyer and exit from Chapter 11 by late July,” Reuters reported. Invitae said in a news release that it…
Hospital Lab Outreach Selloffs Continue with Labcorp as Buyer
By Scott Wallask | From the Volume XXX, No. 11 – July 31, 2023 Issue
OVER THE LAST FEW MONTHS, Labcorp has shaken up the hospital laboratory market in the Pacific Northwest, particularly as it concerns lab outreach services. …
PerkinElmer Says California Terminated COVID-19 Contract
By Robert Michel | From the Volume XXIX, No. 5 – April 4, 2022 Issue
ACCORDING TO A NEW SECURITIES FILING FROM PERKINELMER, the State of California served notice of termination of the company’s contract to run the beleaguered Valencia Branch Laboratory (VBL). PerkinElmer, a diagnostics firm based in Waltham, Mass., made the surprising announcement a…
January 31, 2022 Intelligence: Late-Breaking Lab News
By Robert Michel | From the Volume XXIX, No. 2 – January 31, 2022 Issue
DNA-based breast cancer testing is taking a step forward. Illumina in San Diego, which sells next-generation sequencing (NGS) technology, announced a partnership with Agendia in Irvine, Calif., to develop in vitro diagnostic tests for oncology. Agendia offers proprietary breast …
How Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized